Bora Pharmaceutical Laboratories has added roller compaction technology to the solid dose capability offerings at its Zhunan, Taiwan contract manufacturing and packaging facility. The Zhunan facility is responsible for the manufacture of complex oral solid dose (OSD) formulations with expertise in the use of solvents, Wurster Coating, or Extrusion-Spheronization.
Roller compaction technology will add additional solid dose processing capabilities to the site and to Bora’s contract services offerings. “The successful installation of this roller compactor demonstrates that Bora Pharmaceuticals is committed to meeting the changing needs of our clients and their products,” said Tom Chang, President, Bora Pharmaceutical Laboratories. “The investment is testament to our dedication to providing the highest quality products and ensuring we have the flexibility and capabilities to support our clients for years to come.”
In addition to completing US FDA Inspections, the Zhunan site has completed cGMP inspections by the MHRA and the TFDA and is TAA Compliant. The facility is one of Bora’s three contract manufacturing sites and manufactures products for the North American and European markets. The company recently announced it had completed the acquisition of GSK’s Mississauga, Ontario (Canada) facility. The site represents Bora Pharmaceuticals’ first manufacturing facility in North America and will become home to its headquarters in the region.